TABLE 3.

HDAC related clinical trials started after 2017 for lymphoma treatment.

NCT number	Condition	Intervention	Status	Phase	Start date
NCT03934567	FL	Abexinostat	Recruit	II	20190502
NCT03770000	R/R T-cell Lymphoma	Tenalisib + Romidepsin	Recruit	I/II	20181210
NCT03600441	FL	Abexinostat	Active	II	20180726
NCT03873025	R/R DLBCL	CXD101 + Pembrolizumab	Not yet recruit	I/II	20190313
NCT03820596	R/R Extranodal NKTCL	Sintilimab + Chidamide	Recruit	I/II	20190129
NCT03547700	PTCL	Romidepsin + Ixazomib	Recruit	I/II	20180606
NCT03630731	R/R Extranodal NKTCL	Chidamide	Recruit	II	20180815
NCT04233294	R/R HL	Chidamide + Camrelizumab with or w/o Decitabine	Recruit	II	20200118
NCT04038411	R/R NKTCL	PD-1 Antibody, Chidamide, Lenalidomide Etoposide	Recruit	IV	20190630
NCT04040491	newly diagnosed PTCL	PD-1 Antibody, Chidamide, Lenalidomide Etoposide	Recruit	IV	20190131
NCT04231448	Newly Diagnosed Double-Expressor DLBCL	R-CHOP + Tucidinostat	Not Yet recruit	III	20200108
NCT03373019	R/R DLBCL	Chidamide + R-GDP	Recruit	II	20171214
NCT04337606	R/R NHL	Chidamide + Decitabine + Camrelizumab	Recruit	I/II	20200407
NCT03161223	PTCL	Durvalumab Pralatrexate Romidepsin 5-Azacitidine	Recruit	I/II	20170519
NCT02943642	Mycosis Fungoides	A-dmDT390-bisFv(UCHT1) vs. Vorinostat	Not Yet Recruit	II	20161025
NCT03713320	CTCL, MF	Cobomarsen vs. Vorinostat	Active	II	20181019
NCT03936153	R/R DLBCL	abexinostat	Recruit	II	20190503
NCT03939182	DLBCL, MCL	Abexinostat + Ibrutinib	Recruit	I/II	20190506
NCT04024696	NHL	Abexinostat	Recruit	I/II	20190718
NCT03179930	R/R lymphoma	Entinostat + Pembrolizumab	Recruit	II	20170607
NCT03150329	R/R DLBCL, FL, or HL	Vorinostat + Pembrolizumab	Recruit	I	20170512
NCT03117751	acute lymphoblastic lymphoma	CHOP Pegaspargase Erwinase® Cytarabine Mercaptopurine Dasatinib Methotrexate Blinatumomab Ruxolitinib Bortezomib Dexamethasone Doxorubicin Etoposide Clofarabine Vorinostat Idarubicin Nelarabine Thioguanine	Recruit	II/III	20170418

Retrieved from: http://clinicaltrials.gov/.